Navigation Links
Eniva USA Efacor(R) Fish Oil (Non-Fishy Lemon Taste) Receives ConsumerLab.com Seal of Approval
Date:8/4/2008

MINNEAPOLIS, Aug. 4 /PRNewswire/ -- Another Eniva nutraceutical moves to the forefront of those supplements known for their excellent quality and valid claims. Eniva's Efacor has recently received industry recognition for ensuring product quality standards from ConsumerLab.com. ConsumerLab.com (CL) has long been recognized as the "gold-testing standard" for safety and quality among nutritional products. CL's stringent testing of the Eniva Efacor product has resulted in CL's issuance of its "Approved Quality" seal, or stamp of quality approval, for the Omega-3 dietary supplement.

As an independent certification company, ConsumerLab.com -- usually known by their "CL" initials -- provides testing for a large number of dietary and healthcare manufacturers. Products are tested for specific ingredient claims and held to additional quality standards. In a competitive consumer environment, the CL approval seal is an added mark of assurance for individuals consuming a dietary or health product.

The CL "Approved Quality" seal will be appearing on all Efacor bottles. Responding to the approval, Eniva Chief Medical Officer, Dr. Benjamin Baechler said, "With so much emphasis on heart health today, consumers are looking for Omega-3 products. With Efacor, the consumer is not only getting the supplement they need, they are getting a product that is produced with the values of exceptional quality, safety and effectiveness. Plus, its high dose EPA and DHA are also excellent for the eyes, joints and brain." Added Eniva CEO Andrew Baechler, "We have always believed our Efacor product was outstanding in terms of innovation and impact ... now we can even more confidently share that reassuring news with others who are seeking a healthy way to get their daily needs met for omega-3s."

Research has shown that a diet rich in omega-3s, particularly EPA and DHA, can help support normal and healthy blood pressure, cardiac health, normal brain development and function,
'/>"/>

SOURCE Eniva
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alexs Lemonade Stand Foundation Join facebook(R)
2. Thirsty for a Cause? Try Some Virtual Lemonade!
3. MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alexs Lemonade Stand Foundation
4. Sour comes after a lemon has gone
5. Kids Squeeze Aid Out of Lemons as Take a Stand(R) Program Launches Nationwide
6. True Orange Joins the True Lemon & True Lime Family
7. Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program
8. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
9. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
10. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
11. Go Healthy Receives Letter of Recognition From the Texas Chiropractic Association
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 1Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 3Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 4Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 5Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 7Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 8CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 1CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 2Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 1Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 2